GEMPHARMATECH CO., LTD. — Investor Relations & Filings
About GEMPHARMATECH CO., LTD.
GemPharmatech Co., Ltd. is a global biotechnology company specializing in the development and distribution of genetically engineered mouse models (GEMMs) for biomedical research. The company maintains one of the world's largest repositories of mouse strains, including knockout (KO), conditional knockout (cKO), and humanized models designed for oncology, immunology, and metabolic disease studies. Through its Knockout All Project, GemPharmatech aims to create KO and cKO strains for all protein-coding genes in the mouse genome. Beyond model production, the company provides comprehensive preclinical services such as efficacy testing, safety assessment, phenotyping, and customized gene editing using CRISPR/Cas9 technology. Serving pharmaceutical enterprises, biotechnology firms, and academic institutions, GemPharmatech supports drug discovery and fundamental life science research with high-throughput production capabilities and specialized germ-free mouse facilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 药康生物2022年三季度报告 | 2022-10-30 | Chinese | |
| 关于召开2022年第二次临时股东大会的通知 | 2022-10-30 | Chinese | |
| 监事会关于公司2022年限制性股票激励计划（草案）的核查意见 | 2022-10-30 | Chinese | |
| 2022年限制性股票激励计划（草案）摘要公告 | 2022-10-30 | Chinese | |
| 第一届监事会第八次会议决议公告 | 2022-10-30 | Chinese | |
| 第一届董事会第十五次会议决议公告 | 2022-10-30 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
15 filings
| |||||
| 39529011 | 药康生物2022年三季度报告 | 2022-10-30 | Chinese | ||
| 39528990 | 关于召开2022年第二次临时股东大会的通知 | 2022-10-30 | Chinese | ||
| 39528980 | 监事会关于公司2022年限制性股票激励计划（草案）的核查意见 | 2022-10-30 | Chinese | ||
| 39528971 | 2022年限制性股票激励计划（草案）摘要公告 | 2022-10-30 | Chinese | ||
| 39528968 | 第一届监事会第八次会议决议公告 | 2022-10-30 | Chinese | ||
| 39528964 | 第一届董事会第十五次会议决议公告 | 2022-10-30 | Chinese | ||
| 39528953 | 华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司首次公开发行网下配售限售股上市流通的核查意见 | 2022-10-17 | Chinese | ||
| 39528943 | 关于首次公开发行网下配售限售股上市流通的公告 | 2022-10-17 | Chinese | ||
| 39528913 | 关于参股公司增资的自愿性披露公告 | 2022-09-27 | Chinese | ||
| 39528871 | 华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司2022年半年度持续督导跟踪报告 | 2022-09-07 | Chinese | ||
| 39528860 | 《董事会秘书工作细则》（2022年8月） | 2022-08-19 | Chinese | ||
| 39528854 | 药康生物第一届监事会第七次会议决议公告 | 2022-08-19 | Chinese | ||
| 39528848 | 《信息披露暂缓与豁免业务管理制度》 | 2022-08-19 | Chinese | ||
| 39528841 | 《内幕信息及知情人管理制度》（2022年8月） | 2022-08-19 | Chinese | ||
| 39528834 | 药康生物 2022 年半年度募集资金存放与实际使用情况的专项报告 | 2022-08-19 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
GEMPHARMATECH CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58096/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58096 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58096 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58096 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58096}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GEMPHARMATECH CO., LTD. (id: 58096)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.